|
|
Abstract
SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves seru
F. Palella1, P. Tebas2, B. Gazzard3, P. Ruane4, D. Shamblaw5, J. Flamm6, M. Fisher7, J. van Lunzen8, R. Ebrahimi9, K. White9, B. Guyer9, H. Graham9, T. Fralich9
Background: Antiretroviral regimen simplification improves both quality of life, and long-term medication adherence while reducing the risk of HIV virologic failure (VF) and long-term drug-related toxicities. FTC/RPV/TDF is a well-tolerated, once daily STR treatment option. This is the first study to evaluate the efficacy and safety of switching from boosted Protease Inhibitor (PI) based HAART to a simplified regimen of FTC/RPV/TDF STR.
Methods: A randomized, open-label, multi-center, international, 48 week study to evaluate the safety and efficacy of switching from ritonavir-boosted PI regimens to FTC/RPV/TDF in virologically-suppressed (HIV RNA< 50 copies/mL), HIV-1 infected subjects. Participants were randomized 2:1 to switch to FTC/RPV/TDF or maintain their current PI-based regimen. The primary endpoint was non-inferiority (12% margin) of FTC/RPV/TDF relative to PI-based regimens in maintaining plasma HIV-1 RNA< 50 copies/mL at Week 24 by Snapshot analysis. Changes in serum lipids from baseline were evaluated.
Results: A total of 476 subjects were randomized and received at least 1 dose of study drug (317 FTC/RPV/TDF; 159 PI). Baseline characteristics were similar (table 1). Switching to FTC/RPV/TDF was non-inferior to maintaining a ritonavir-boosted PI regimen (93.4% versus 89.9%) at Week 24 for HIV RNA< 50 copies/mL (95% CI [-2.0%, 8.9%]). Fewer subjects in the FTC/RPV/TDF arm than the PI arm had virologic failure by Snapshot, defined as HIV RNA≥50 copies/mL at Week 24 or discontinuations of study drug with HIV RNA≥50 copies/mL (1.3% vs 5.0%). Two subjects in the FTC/RPV/TDF arm had emergent resistance and one in the PI arm. Overall total cholesterol, LDL, and triglycerides decreased to a greater extent among FTC/RPV/TDF than PI recipients (table 2).
| | FTC/RPV/TDF | PI | | Males (%) | 86.1 | 90.6 | | Black or African Heritage (%) | 19.2 | 13.8 | | Age (mean, years) | 41 | 43 | | CD4 (mean, cells/mm3) | 576 | 600 |
| | Baseline | Mean Change at
Week 24 | | | | FTC/RPV/TDF | PI | FTC/RPV/TDF | PI | p value | | Total Cholesterol (mg/dL) | 192 | 194 | -25 | -1 | <0.001 | | LDL (mg/dL) | 121 | 124 | -16 | 0 | <0.001 | | Triglycerides (mg/dL) | 163 | 173 | -53 | 3 | <0.001 | | HDL (mg/dL) | 53 | 50 | -4 | -1 | <0.001 | | Total Cholesterol/HDL | 3.86 | 4.08 | -0.27 | 0.08 | <0.001 |
Conclusions: Switching to the FTC/RPV/TDF STR from a ritonavir-boosted PI regimen in virologically-suppressed, HIV-1-infected participants maintains virologic suppression with low risk of virologic failure while improving total cholesterol, LDL, and triglycerides.
19th International AIDS Conference
Abstract no.
TUAB0104
Suggested Citation
"F.Palella, et al.
SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves seru.
:
19th International AIDS Conference:
Abstract no.
TUAB0104 "
|
|
|